€ million |
|
Note |
|
2022 |
|
2021 |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit after tax |
|
|
|
3,339 |
|
3,065 |
||||||
Depreciation/amortization/impairment losses/reversals of impairment losses1 |
|
|
|
2,030 |
|
1,767 |
||||||
Changes in inventories |
|
|
|
-604 |
|
-472 |
||||||
Changes in trade accounts receivable |
|
|
|
-413 |
|
-310 |
||||||
Changes in trade accounts payable/refund liabilities |
|
|
|
101 |
|
433 |
||||||
Changes in provisions |
|
|
|
113 |
|
196 |
||||||
Changes in other assets and liabilities |
|
|
|
-279 |
|
-121 |
||||||
Neutralization of gains/losses on disposal of fixed assets and other disposals |
|
|
|
-48 |
|
-24 |
||||||
Other non-cash income and expenses1 |
|
|
|
21 |
|
81 |
||||||
Operating Cash Flow |
|
|
4,259 |
|
4,616 |
|||||||
|
|
|
|
|
|
|
||||||
Payments for investments in intangible assets |
|
|
|
-275 |
|
-355 |
||||||
Payments from the disposal of intangible assets |
|
|
|
38 |
|
39 |
||||||
Payments for investments in property, plant and equipment |
|
|
|
-1,531 |
|
-1,066 |
||||||
Payments from the disposal of property, plant and equipment |
|
|
|
21 |
|
7 |
||||||
Payments for investments in financial assets |
|
|
|
-364 |
|
-269 |
||||||
Payments for acquisitions less acquired cash and cash equivalents (net) |
|
|
|
-854 |
|
-4 |
||||||
Proceeds from the disposal of other financial assets |
|
|
|
219 |
|
69 |
||||||
Payments for the acquisition of non-financial assets |
|
|
|
-600 |
|
– |
||||||
Proceeds from the disposal of non-financial assets |
|
|
|
600 |
|
– |
||||||
Payments from divestments |
|
|
|
4 |
|
1 |
||||||
Investing Cash Flow |
|
|
-2,743 |
|
-1,578 |
|||||||
|
|
|
|
|
|
|
||||||
Dividend payments to shareholders of Merck KGaA, Darmstadt, Germany |
|
|
|
-239 |
|
-181 |
||||||
Dividend payments to non-controlling interests |
|
|
|
-11 |
|
-8 |
||||||
Profit withdrawal by E. Merck KG, Darmstadt, Germany |
|
|
|
-716 |
|
-567 |
||||||
Proceeds from new borrowings of financial debt from E. Merck KG, Darmstadt, Germany, and E. Merck Beteiligungen KG, Darmstadt, Germany, a related party of E. Merck KG, Darmstadt, Germany2 |
|
|
|
1,637 |
|
471 |
||||||
Repayment of financial debt to E. Merck KG, Darmstadt, Germany |
|
|
|
-1,613 |
|
-393 |
||||||
Repayment of bonds |
|
|
|
-1,661 |
|
-317 |
||||||
Proceeds from the issuance of bonds |
|
|
|
995 |
|
– |
||||||
Payments from new borrowings of other current and non-current financial debt |
|
|
|
1,281 |
|
388 |
||||||
Repayment of other current and non-current financial debt |
|
|
|
-1,227 |
|
-1,896 |
||||||
Financing Cash Flow |
|
|
-1,555 |
|
-2,504 |
|||||||
|
|
|
|
|
|
|
||||||
Changes in cash and cash equivalents |
|
|
|
-39 |
|
534 |
||||||
Changes in cash and cash equivalents due to currency translation |
|
|
|
-7 |
|
9 |
||||||
Cash and cash equivalents as of January 1 |
|
|
|
1,899 |
|
1,355 |
||||||
Cash and cash equivalents as of December 31 (consolidated balance sheet) |
|
|
1,854 |
|
1,899 |
|||||||
|
||||||||||||